Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last I I were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol I Plus 2) showed a significant Survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in Correspondence with the RTOG- and EORTC-RPA Subclasses. The median Survival time (MST) was 15.6 months for protocols I and 2 together. For protocol 2, the MST was 23.5 months. The main causes Of death were cerebrospinal fluid dissemination as well Lis local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.